• VVT Med entered a 12-month trial distribution agreement with Ebtec to evaluate ScleroSafe in Panama, effective Oct. 5, 2026.
• Ebtec will serve as importer and conditionally exclusive trial distributor, subject to training, regulatory compliance and purchase obligations.
• The agreement requires at least 10 full sets within 14 days of effectiveness, then at least 10 more within six months.
• Satisfactory performance could lead to negotiations for a separate five-year exclusive distribution agreement, subject to mutual agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VVT Med Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610220700CANADANWCANADAPR_C6287) on October 22, 2026, and is solely responsible for the information contained therein.